American College of Clinical Pharmacy
      Search      Cart
         

Residents, Fellows, and Graduate Students

Welcome to the Resident and Fellow section of the ACCP Web site. As a postgraduate trainee, you have the opportunity to benefit from all of the educational programs and resources available to full members, but at a discounted membership rate. You can also utilize the career development and networking tools that will help you reach the next step in your career path.

Announcements

ACCP Launches On-Demand Letter of Intent Review Service
New service is available for student and trainee members. Learn more.
Take Advantage of ACCP’s On Demand CV Review Service
Postgraduate trainee members of ACCP can now submit their curriculum vitae online and have it reviewed by an ACCP member. Learn more.

Social Media

ACCP Podcasts for Residents by Residents
Comments and questions about resident podcasts can be sent to resfel@list.accp.com or ksims@accp.com.

Episode 36: ACCP Podcast for Residents by Residents: Andexanet

Click an icon to listen.

Google Play
Apple Podcasts
  • Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
  • AndexXa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, May 2018.
  • Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-41.
  • Crowther MA, Kittl E, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost 2013;11(suppl 2):OC 20.1.
  • Crowther MA, Lu G, Conley P, et al. Reversal of factor Xa inhibitors-induced anticoagulation in healthy subjects by andexanet alfa. Crit Care Med 2014;42:A1469.
  • Crowther MA, Mathur V, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Blood 2013;122:3636.
  • EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
  • Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015;385:2077-87.
  • Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
  • Guigliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
  • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
  • Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-24.

Episode 35: ACCP Podcast for Residents by Residents: Paving Your Way in Ambulatory Care.

Click an icon to listen.

Google Play
Apple Podcasts

Additional Reading

Episode 34: ACCP Podcast for Residents by Residents: Mentorship.

Click an icon to listen.

Google Play
Apple Podcasts

Additional Reading

Episode 33: ACCP Podcast for Residents by Residents: How to stay current with the primary literature.

Click an icon to listen.

Google Play
Apple Podcasts

Episode 32: ACCP Podcast for Residents by Residents: The 1 Hour Sepsis Bundle.

Click an icon to listen.

Google Play
Apple Podcasts
  • Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017; 45:486-552.
  • Levy MM, et al. The Surviving Sepsis Campaign Bundle: 2018 Update. Crit Care Med. 2018. 46(6):997-1000.
  • Seymour CW, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N Engl J Med. 2017; 376:2235-44.
  • Kumar, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34(6):1589-1596.
  • Jones SL, et al. Outcomes and Resource Use of Sepsis-associated Stays by Presence on Admission, Severity, and Hospital Type. Medical Care. 2016; 54(3):303-310.